Nuveen’s Kite Pharma, Inc. KITE Stock Holding History

Nuveen’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-9,352	Closed	-$970K	–	1197
2017 Q2	$970K	Buy	+9,352	New	+$763K	0.01%	764
2017 Q1	–	Sell	-24,503	Closed	-$1.1M	–	1561
2016 Q4	$1.1M	Buy	24,503 +4,356	+22%	+$214K	0.01%	1116
2016 Q3	$1.13M	Sell	20,147 -279	-1%	-$15.5K	0.01%	1037
2016 Q2	$1.02M	Buy	20,426 +4,761	+30%	+$234K	0.01%	1017
2016 Q1	$720	Buy	+15,665	New	+$759K	﹤0.01%	1139
2015 Q3	–	Sell	-11,981	Closed	-$730	–	1655
2015 Q2	$730	Buy	+11,981	New	+$684K	﹤0.01%	1269

Other funds holding KITE

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCSAM

Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Nuveen's KITE Position: Q3 2017 in Review

Nuveen sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 9,352 shares — an estimated $970K sold.

Nuveen first reported a position in KITE in Q2 2015 and held it in 6 quarters. The position peaked at $1.13M in Q3 2016. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

Nuveen reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
Nuveen sold 9,352 Kite Pharma, Inc. shares in Q3 2017, an estimated $970K.
Nuveen first reported a position in Kite Pharma, Inc. in Q2 2015 and held it in 6 quarters.
Nuveen's Kite Pharma, Inc. position peaked at $1.13M in Q3 2016.
244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Nuveen's 13F filing for Q3 2017, filed 14 Nov 2017.